Skin Cancer & Melanoma

Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.

Intismeran autogene plus pembrolizumab cut the risk of recurrence or death by 42% vs pembrolizumab alone in resected stage IIB-IV melanoma.

Cosibelimab is now a preferred, category 2A NCCN option for locally advanced CSCC when curative surgery or radiation is not feasible.

Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.

The FDA approved the first and only photodynamic therapy for the treatment of a skin cancer.

Matteo S. Carlino, MD, PhD, FRACP, discussed V940 plus pembrolizumab data, safety, and administration in resected melanoma.

Final COMBI-I data show a survival advantage with spartalizumab plus dabrafenib/trametinib over dabrafenib/trametinib alone in BRAF V600-mutant melanoma.

Results from the INTERpath-001 trial of V0940 plus pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in resected melanoma.

The FDA approved the PGDx elio tissue complete CDx to identify patients with advanced melanoma with BRAF V600E/K variants eligible for targeted therapy.

The FDA has approved RP1 plus nivolumab for adults with advanced melanoma who progressed on anti–PD-1 therapy.

Researchers have reported the first known case of TIL therapy in a patient with well-controlled HIV and metastatic melanoma.

The FDA's CTGTAC voted 10-3 in favor RP1 plus nivolumab's benefit-risk profile in anti–PD-1–resistant advanced melanoma.

As the FDA's ODAC prepares to weigh in ahead of an August 2, 2026, decision date, take a look at RP1's clinical trial and regulatory journey.

Miguel A. Materin, MD, discussed insights on multidisciplinary care, intra-arterial chemotherapy, and the evolving landscape of uveal melanoma treatments.

Miguel A. Materin, MD, discussed his new leadership role at Northwell Cancer Institute, and why a multidisciplinary approach is critical to managing ocular malignancies.

FDA breakthrough designation and NCCN inclusion elevate Merlin CP-GEP as a tool to refine SLNB decisions in T1b/T2a melanoma, per MERLIN_001 trial data.

In this patient case, a 72-year-old male with primary malignant melanoma of the ascending colon received adjuvant therapy consisting of immunotherapy with PD-1 inhibitors.

The FDA has accepted a BLA resubmission for RP1 plus nivolumab for patients with advanced melanoma.

Binimetinib tablets at 45 mg received tentative FDA approval for patients with melanoma and NSCLC.

A panel of exerts discussed key takeaways happening in the field of cutaneous squamous cell carcinoma.

Sarah Weiss, MD, highlights pivotal updates in uveal melanoma, intratumoral neoadjuvant therapy, and Merkel cell carcinoma from the 2026 ASCO Annual Meeting.

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer, all from ASCO 2026.

Findings from the OptimUM-02 trial may support a new potential therapeutic standard for patients with HLA-A*02:01–negative metastatic uveal melanoma.

Neoadjuvant ipilimumab plus nivolumab and relatlimab achieved a major pathologic response in 73.7% of patients with resectable stage III/IV melanoma.

Data from the KEYNOTE-942 trial confirmed a durable benefit with intismeran plus pembrolizumab among patients with high-risk melanoma.